Fig 6.

The antitumorgenesis activity at various doses and regimens of TSL-1. (A) Nude mice were inoculated with adenocarcinoma (H441) NSCLC cells on the right flank of skin. The control group received double distilled water (vehicle), and other group received 3 different TSL-1 treatments for 35 days. Group 1 mice were treated with a low dose (1 g/kg body weight [Bwt]) of TSL-1 via PO; group 2 mice were treated with a high dose (5 g/kg Bwt) of TSL-1 via PO; and group 3 mice were treated with a high dose (50 mg/kg Bwt) of of TSL-1 intraperitoneally. (B) Nude mice were pretreated (PO) with TSL-1 or vehicle (DDW) for 30 days; the nude mice were then inoculated with adenocarcinoma (H441) through the skin after tumor formation control groups received distilled water for 42 days, where as the other 2 groups were treated for an additional 42 days as follows: group a: TS-DW received double distilled water and group b: TS-TS received 1 g/kg Bwt of TSL-1 for an additional 42 days. The data are presented as mean ± SD (n = 7). ^∗∗P < 0.01 represents the level of significance of differences between control and TSL-1 treatment. ^##P < 0.01 represents the level significant of differences between groups a and b at 42 days.